We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas.
- Authors
Barnhoorn, Marieke C; Wasser, Martin N J M; Roelofs, Helene; Maljaars, P W Jeroen; Molendijk, Ilse; Bonsing, Bert A; Oosten, Liesbeth E M; Dijkstra, Gerard; Woude, C Janneke van der; Roelen, Dave L; Zwaginga, Jaap-Jan; Verspaget, Hein W; Fibbe, Willem E; Hommes, Daniel W; Peeters, Koen C M J; Jong, Andrea E van der Meulen-de
- Abstract
Background and Aims The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell [bmMSC] therapy in perianal Crohn's disease [CD] fistulas is unknown. We aimed to provide a 4-year clinical evaluation of allogeneic bmMSC treatment of perianal CD fistulas. Methods A double-blind dose-finding study for local bmMSC therapy in 21 patients with refractory perianal fistulising Crohn's disease was performed at the Leiden University Medical Center in 2012–2014. All patients treated with bmMSCs [1 x 107 bmMSCs cohort 1, n = 5; 3 × 107 bmMSCs cohort 2, n = 5; 9 × 107 bmMSCs cohort 3, n = 5] were invited for a 4-year evaluation. Clinical events were registered, fistula closure was evaluated, and anti-human leukocyte antigen [HLA] antibodies were assessed. Patients were also asked to undergo a pelvic magnetic resonance imaging [MRI] and rectoscopy. Results Thirteen out of 15 patients [87%] treated with bmMSCs were available for long-term follow-up. Two non-MSC related malignancies were observed. No serious adverse events thought to be related to bmMSC therapy were found. In cohort 2 [ n = 4], all fistulas were closed 4 years after bmMSC therapy. In cohort 1 [ n = 4] 63%, and in cohort 3 [ n = 5] 43%, of the fistulas were closed, respectively. In none of the patients anti-HLA antibodies could be detected 24 weeks and 4 years after therapy. Pelvic MRI showed significantly smaller fistula tracts after 4 years. Conclusions Allogeneic bmMSC therapy for CD-associated perianal fistulas is also in the long-term a safe therapy. In bmMSC-treated patients, fistulas with closure at Week 24 were still closed after 4 years.
- Publication
Journal of Crohn's & Colitis, 2020, Vol 14, Issue 1, p64
- ISSN
1873-9946
- Publication type
Article
- DOI
10.1093/ecco-jcc/jjz116